The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study
Authors' conclusion
A high proportion of individual patients achieving clinical endpoints at IP week 24 with abatacept + methotrexate sustained their responses through week 52. Of patients achieving early and sustained SDAI remission through 52 weeks, numerically more maintained remission during the DE period if weekly abatacept treatment continued.
Study context
- Population
- MTX-naive, ACPA-positive patients with early (≤ 6 months), active RA451 on abatacept + MTX
- Participants
- 752 participants
- Comparison
- Abatacept + MTX vs abatacept placebo + MTX; in de-escalation (DE) period, continued weekly abatacept + MTX vs abatacept monotherapy vs de-escalation/withdrawal of abatacept
- Primary endpoint
- Week 24 SDAI remission; this subanalysis: sustained SDAI remission to 1 year and its maintenance after changes in therapy
- Follow-up
- Week 24
Methodological detailsphase IIIb, two-stage, re-randomised de-escalation period
- Phase IIIb
- Two-stage
- Re-randomised de-escalation period
Primary result
As reported in the abstract
SDAI remission at end of DE period, among patients with sustained response at IP weeks 24/40/52
Further findings
Response at induction period (IP) week 24 with abatacept + MTX, and proportion sustaining it through IP weeks 40/52
- Simplified Disease Activity Index (SDAI) remission at week 24
- 22%
- Boolean remission at week 24
- 17%
- DAS28-CRP < 2.6 at week 24
- 42%
- Sustained SDAI remission through weeks 40/52
- 56%
- Sustained Boolean remission through weeks 40/52
- 58%
- Sustained DAS28-CRP < 2.6 through weeks 40/52
- 74%
Original publication
The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study. Arthritis Res Ther. Published 22 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →